Targeting metastasis-initiating cells through the fatty acid receptor CD36
The fact that the identity of the cells that initiate metastasis in most human cancers is unknown hampers the development of antimetastatic therapies. Here we describe a subpopulation of CD44bright cells in human oral carcinomas that do not overexpress mesenchymal genes, are slow-cycling, express high levels of the fatty acid receptor CD36 and lipid metabolism genes, and are unique in their ability to initiate metastasis. Palmitic acid or a high-fat diet specifically boosts the metastatic potential of CD36+ metastasis-initiating cells in a CD36-dependent manner. The use of neutralizing antibodies to block CD36 causes almost complete inhibition of metastasis in immunodeficient or immunocompetent orthotopic mouse models of human oral cancer, with no side effects. Clinically, the presence of CD36+ metastasis-initiating cells correlates with a poor prognosis for numerous types of carcinomas, and inhibition of CD36 also impairs metastasis, at least in human melanoma- and breast cancer-derived tumours. Together, our results indicate that metastasis-initiating cells particularly rely on dietary lipids to promote metastasis..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:541 |
---|---|
Enthalten in: |
Nature |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gloria Pascual [VerfasserIn] |
---|
Links: |
---|
doi: |
10.1038/nature20791 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC1988100577 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | OLC1988100577 | ||
003 | DE-627 | ||
005 | 20230715020901.0 | ||
007 | tu | ||
008 | 170207s2017 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1038/nature20791 |2 doi | |
028 | 5 | 2 | |a PQ20170301 |
035 | |a (DE-627)OLC1988100577 | ||
035 | |a (DE-599)GBVOLC1988100577 | ||
035 | |a (PRQ)c1461-59fd3d6bb9ef583a498cbfdb405467459a3cf19ba4da3c9e7d6e95882350bb760 | ||
035 | |a (KEY)0072945020170000541763500041targetingmetastasisinitiatingcellsthroughthefattya | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 070 |a 500 |q DE-101 |
082 | 0 | 4 | |a 500 |q AVZ |
084 | |a BIODIV |2 fid | ||
100 | 0 | |a Gloria Pascual |e verfasserin |4 aut | |
245 | 1 | 0 | |a Targeting metastasis-initiating cells through the fatty acid receptor CD36 |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
520 | |a The fact that the identity of the cells that initiate metastasis in most human cancers is unknown hampers the development of antimetastatic therapies. Here we describe a subpopulation of CD44bright cells in human oral carcinomas that do not overexpress mesenchymal genes, are slow-cycling, express high levels of the fatty acid receptor CD36 and lipid metabolism genes, and are unique in their ability to initiate metastasis. Palmitic acid or a high-fat diet specifically boosts the metastatic potential of CD36+ metastasis-initiating cells in a CD36-dependent manner. The use of neutralizing antibodies to block CD36 causes almost complete inhibition of metastasis in immunodeficient or immunocompetent orthotopic mouse models of human oral cancer, with no side effects. Clinically, the presence of CD36+ metastasis-initiating cells correlates with a poor prognosis for numerous types of carcinomas, and inhibition of CD36 also impairs metastasis, at least in human melanoma- and breast cancer-derived tumours. Together, our results indicate that metastasis-initiating cells particularly rely on dietary lipids to promote metastasis. | ||
650 | 4 | |a Bladder cancer | |
650 | 4 | |a Lipids | |
650 | 4 | |a Cell cycle | |
650 | 4 | |a Fatty acids | |
650 | 4 | |a Population | |
650 | 4 | |a Breast cancer | |
650 | 4 | |a Tumors | |
650 | 4 | |a Medical prognosis | |
650 | 4 | |a Metabolism | |
650 | 4 | |a Lymphatic system | |
650 | 4 | |a Metastasis | |
650 | 4 | |a Melanoma | |
650 | 4 | |a Gene expression | |
650 | 4 | |a Health aspects | |
650 | 4 | |a Cancer cells | |
650 | 4 | |a Lipid metabolism | |
650 | 4 | |a Genetic aspects | |
700 | 0 | |a Alexandra Avgustinova |4 oth | |
700 | 0 | |a Stefania Mejetta |4 oth | |
700 | 0 | |a Mercè Martín |4 oth | |
700 | 0 | |a Andrés Castellanos |4 oth | |
700 | 0 | |a Camille Stephan-Otto Attolini |4 oth | |
700 | 0 | |a Antoni Berenguer |4 oth | |
700 | 0 | |a Neus Prats |4 oth | |
700 | 0 | |a Agustí Toll |4 oth | |
700 | 0 | |a Juan Antonio Hueto |4 oth | |
700 | 0 | |a Coro Bescós |4 oth | |
700 | 0 | |a Luciano Di Croce |4 oth | |
700 | 0 | |a Salvador Aznar Benitah |4 oth | |
773 | 0 | 8 | |i Enthalten in |t Nature <London> |d London : Macmillan, 1869 |g 541(2017), 7635, Seite 41-45 |w (DE-627)129292834 |w (DE-600)120714-3 |w (DE-576)014473941 |x 0028-0836 |7 nnns |
773 | 1 | 8 | |g volume:541 |g year:2017 |g number:7635 |g pages:41-45 |
856 | 4 | 1 | |u http://dx.doi.org/10.1038/nature20791 |3 Volltext |
856 | 4 | 2 | |u http://search.proquest.com/docview/1856850661 |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-BIODIV | ||
912 | |a SSG-OLC-PHY | ||
912 | |a SSG-OLC-CHE | ||
912 | |a SSG-OLC-MAT | ||
912 | |a SSG-OLC-FOR | ||
912 | |a SSG-OLC-SPO | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a SSG-OPC-FOR | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_14 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_47 | ||
912 | |a GBV_ILN_48 | ||
912 | |a GBV_ILN_59 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_135 | ||
912 | |a GBV_ILN_154 | ||
912 | |a GBV_ILN_168 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_211 | ||
912 | |a GBV_ILN_252 | ||
912 | |a GBV_ILN_290 | ||
912 | |a GBV_ILN_294 | ||
912 | |a GBV_ILN_601 | ||
912 | |a GBV_ILN_647 | ||
912 | |a GBV_ILN_754 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2002 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2016 | ||
912 | |a GBV_ILN_2018 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2095 | ||
912 | |a GBV_ILN_2116 | ||
912 | |a GBV_ILN_2120 | ||
912 | |a GBV_ILN_2121 | ||
912 | |a GBV_ILN_2219 | ||
912 | |a GBV_ILN_2221 | ||
912 | |a GBV_ILN_2279 | ||
912 | |a GBV_ILN_2286 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4219 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4277 | ||
912 | |a GBV_ILN_4302 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4314 | ||
912 | |a GBV_ILN_4317 | ||
912 | |a GBV_ILN_4320 | ||
912 | |a GBV_ILN_4324 | ||
951 | |a AR | ||
952 | |d 541 |j 2017 |e 7635 |h 41-45 |